Acasti Pharma ROE 2014-2024 | GRCE
Current and historical return on equity (ROE) values for Acasti Pharma (GRCE) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Acasti Pharma ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-06-30 |
$-0.01B |
$0.06B |
-17.39% |
| 2024-03-31 |
$-0.01B |
$0.06B |
-18.60% |
| 2023-12-31 |
$-0.04B |
$0.07B |
-57.58% |
| 2023-09-30 |
$-0.04B |
$0.07B |
-54.05% |
| 2023-06-30 |
$-0.04B |
$0.06B |
-51.06% |
| 2023-03-31 |
$-0.04B |
$0.07B |
-46.61% |
| 2022-12-31 |
$-0.02B |
$0.10B |
-17.60% |
| 2022-09-30 |
$-0.02B |
$0.10B |
-17.02% |
| 2022-06-30 |
$-0.01B |
$0.10B |
-10.98% |
| 2022-03-31 |
$-0.01B |
$0.11B |
-10.36% |
| 2021-12-31 |
$-0.01B |
$0.11B |
-14.37% |
| 2021-09-30 |
$-0.01B |
$0.11B |
-17.67% |
| 2021-06-30 |
$-0.02B |
$0.05B |
-50.00% |
| 2021-03-31 |
$-0.02B |
$0.06B |
-78.43% |
| 2020-12-31 |
$0.00B |
$0.03B |
20.34% |
| 2020-09-30 |
$-0.01B |
$0.01B |
-85.71% |
| 2020-06-30 |
$-0.02B |
$0.01B |
-466.67% |
| 2020-03-31 |
$-0.03B |
$0.01B |
-1000.00% |
| 2019-12-31 |
$-0.06B |
$-0.01B |
-2750.00% |
| 2019-09-30 |
$-0.05B |
$-0.00B |
-511.11% |
| 2019-06-30 |
$-0.04B |
$0.00B |
-646.15% |
| 2019-03-31 |
$-0.04B |
$0.01B |
-537.93% |
| 2018-12-31 |
$-0.03B |
$0.02B |
-533.33% |
| 2018-09-30 |
$-0.03B |
$-0.01B |
-1046.15% |
| 2018-06-30 |
$-0.02B |
$0.01B |
-233.33% |
| 2018-03-31 |
$-0.02B |
$0.01B |
-154.55% |
| 2017-12-31 |
$-0.01B |
$0.01B |
-94.55% |
| 2017-09-30 |
$-0.01B |
$0.01B |
-68.97% |
| 2017-06-30 |
$-0.01B |
$0.01B |
-50.79% |
| 2017-02-28 |
$-0.01B |
$0.02B |
-47.06% |
| 2016-11-30 |
$-0.01B |
$0.02B |
-45.71% |
| 2016-05-31 |
$-0.01B |
$0.02B |
-40.00% |
| 2016-03-31 |
$-0.01B |
$0.02B |
-30.77% |
| 2015-12-31 |
$-0.01B |
$0.02B |
-23.53% |
| 2015-09-30 |
$-0.00B |
$0.02B |
-3.57% |
| 2015-06-30 |
$-0.00B |
$0.03B |
-10.17% |
| 2015-03-31 |
$-0.00B |
$0.03B |
-3.23% |
| 2014-12-31 |
$-0.00B |
$0.03B |
-6.35% |
| 2014-06-30 |
$-0.01B |
$0.03B |
-28.57% |
| 2014-03-31 |
$-0.01B |
$0.03B |
-54.79% |
| 2013-12-31 |
$-0.01B |
$0.02B |
-74.58% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
